Tigecycline

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Skin Diseases, Infectious

Conditions

Skin Diseases, Infectious

Trial Timeline

Jul 1, 2006 → Aug 1, 2007

NCT ID

NCT00488761

About Tigecycline

Tigecycline is a approved stage product being developed by Pfizer for Skin Diseases, Infectious. The current trial status is completed. This product is registered under clinical trial identifier NCT00488761. Target conditions include Skin Diseases, Infectious.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01560143	Approved	Completed	Mar 1, 2012	May 1, 2012	Obesity
NCT01401023	Pre-clinical	Completed	Jul 1, 2011	Jul 1, 2013	Diarrhea
NCT01072539	Pre-clinical	Completed	May 1, 2010	Apr 1, 2015	Complicated Skin and Skin Structure Infections
NCT00827541	Pre-clinical	Completed	Aug 1, 2008	Dec 1, 2010	Intra-Abdominal Infections
NCT00575094	Phase 3	Completed	Nov 1, 2007	Mar 1, 2008	Community-Acquired Infections
NCT00419991	Approved	Completed	Jan 1, 2007	May 1, 2008	Staphylococcal Infections
NCT00406237	Phase 1	Completed	Dec 1, 2006	Mar 1, 2009	Liver Cirrhosis, Biliary
NCT00488488	Pre-clinical	Completed	Nov 1, 2006	Mar 1, 2010	Infection
NCT00376324	Phase 1	Completed	Sep 1, 2006	Oct 1, 2008	Healthy Subjects
NCT00488306	Approved	Completed	Aug 1, 2006	Aug 1, 2007	Abdominal Abscess
NCT00488761	Approved	Completed	Jul 1, 2006	Aug 1, 2007	Skin Diseases, Infectious
NCT00136201	Phase 3	Completed	Nov 1, 2005	Dec 1, 2006	Abdominal Abscess
NCT00205816	Phase 3	Completed	Jan 1, 2004	Nov 1, 2005	Bacterial Infections
NCT00079989	Phase 3	Completed	Dec 1, 2003	Nov 1, 2005	Gram-Negative Bacterial Infections
NCT00079885	Phase 3	Completed	Nov 1, 2003	Jul 1, 2005	Community Acquired Pneumonia
NCT00079976	Phase 3	Completed	Oct 1, 2003	Jun 1, 2005	Gram-Positive Bacterial Infections
NCT00081744	Phase 3	Completed	Nov 1, 2002	Aug 1, 2004	Gram-Positive Bacterial Infections
NCT00600600	Phase 2	Completed	Apr 1, 2002	Dec 1, 2010	Mycobacterium Abscessus Lung Disease

Competing Products

20 competing products in Skin Diseases, Infectious

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT01 + [212Pb]VMT01 + Nivolumab	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT01 + [68Ga]VMT02	Perspective Therapeutics	Phase 1	25
Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product	Sun Pharmaceutical	Phase 1	33
LY3041658 + Placebo	Eli Lilly	Phase 1	33
DSP-9632P 27.5 mg + DSP-9632P 82.5 mg + Placebo + DSP-9632P 55.0 mg + Levodopa formulation	Sumitomo Pharma	Phase 1	33
levofloxacin	Johnson & Johnson	Phase 2/3	65
Moisturizer A, F#9155-005	Johnson & Johnson	Pre-clinical	23
levofloxacin	Johnson & Johnson	Phase 3	77
Ceftobiprole	Johnson & Johnson	Phase 1	33
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK Cells	Johnson & Johnson	Phase 1	33
Levofloxacin	Johnson & Johnson	Phase 3	77
Ceftobiprole	Johnson & Johnson	Phase 1	33
Levodopa-carbidopa intestinal gel	AbbVie	Phase 3	77
Iressa	AstraZeneca	Phase 2	52
Daptomycin + Vancomycin	AstraZeneca	Phase 3	77
Sarizotan	Merck	Pre-clinical	23
Pembrolizumab + EDP1503	Merck	Phase 2	52
testosterone gel + Comparator: placebo	Merck	Phase 1	33
LNS8801 + Pembrolizumab + Chemotherapy (dacarbazine or temozolomide) + Immunotherapy (Pembrolizumab) + Immunotherapy (nivolumab and relatlimab) + Immunotherapy (ipilimumab and nivolumab)	Merck	Phase 2/3	65
Vancomycin + Daptomycin + Semi-Synthetic Penicillin	Merck	Approved	85

Other Products from Pfizer